Esther Serra-Baldrich

Esther Serra-Baldrich

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Esther Serra-Baldrich has a total of 146 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The State of the Art in Chronic Prurigo Nodularis

    by Esther Serra-Baldrich, Ángeles Flórez, Marc Julià Manresa, Francisco Javier Ortiz de Frutos, José-Juan Pereyra-Rodriguez, Bibiana Pérez, Ignasi Figueras

    Chronic prurigo nodularis (CPN) is a highly burdensome chronic inflammatory dermatosis characterized by intensely pruritic papulonodular lesions that may persist for years. Its pathophysiology reflects a neuro-immune-fibrotic axis in which type-2 cytokines (IL-4/IL-13/IL-31), neuropeptides, and profibrotic signaling interact to sustain the itch-scratch cycle and dermal fibrosis. CPN predominantly affects older adult women and is frequently associated with dermatologic, neuropsychiatric, and cardiometabolic comorbidities. Definition, nomenclature, and management remain areas of debate, with relevant differences between European and US consensus documents. The therapeutic landscape has expanded with dupilumab and nemolizumab, the only agents currently supported by phase III evidence, whereas JAK inhibitors remain promising but investigational options that require careful safety contextualization. This narrative review synthesizes current knowledge on CPN, from definition and epidemiology to etiopathogenesis and evolving therapy, while highlighting persistent unmet needs in diagnosis and management.


  • Open Access

    Recomendaciones para el manejo de la xerosis en la farmacia comunitaria

    by Loida Galvany Rossell, Irene González Orts, Genoveva Osorio Fernandez, Esther Serra Baldrich

    La xerosis o piel seca es una dermatosis común que afecta entre el 15% y el 30% de la población, y a más del 50% de las personas mayores de 65 años. Es tanto una condición en sí misma como un síntoma de otras afecciones (como la dermatitis atópica). Su gravedad depende de la pérdida de agua en el estrato córneo de la piel. La piel seca presenta síntomas de aspereza y descamación, acompañados de malestar y prurito. Este último es el síntoma principal y provoca el rascado, lo que puede dañar la barrera cutánea y generar un ciclo vicioso de picazón y rascado. Puede afectar a cualquier persona, aunque algunas de las poblaciones más afectadas son ancianos, lactantes, personas con antecedentes de dermatitis/eccema, institucionalizadas, con enfermedades crónicas (tumores, diabetes, hipotiroidismo, insuficiencia renal crónica, hepatopatías), en riesgo de malnutrición y expuestas a factores externos (p.ej., profesiones que requieren lavado frecuente de manos, uso de productos químicos o exposición a climas extremos). Está asociada a patologías como la dermatitis (atópica, de contacto, numular, craquelé, etc.) así como a enfermedades infecciosas como el impétigo la foliculitis y el herpes. El farmacéutico comunitario desempeña un papel fundamental en la identificación de la xerosis, el asesoramiento personalizado y la derivación al médico cuando sea necesario, contribuyendo así a mejorar la calidad de vida de los pacientes.

  • Open Access

    Defining the Care Pathway in Patients with Psoriasis and Atopic Dermatitis

    by Montserrat Masip, Neus Pagès-Puigdemont, Anna López-Ferrer, Héctor David de Paz, Esther Serra-Baldrich, Lluís Puig, Pau Riera

    Purpose: This study aims to map the clinical pathway for psoriasis and atopic dermatitis (AD) in a tertiary hospital to better understand patient needs and experiences, thereby suggesting improvements in patient-centered care. Methods: A mixed-method approach was utilised involving a literature review, a questionnaire for healthcare professionals (HCPs), and two focus groups (one with HCPs and the other with patients with psoriasis or AD). Ethical approvals were obtained, and informed consent was acquired from all participants. Results: Patients and HCPs identified significant delays in the pre-diagnosis phase, extending up to five years for psoriasis and three years for AD, adversely affecting the timely initiation of effective treatment. In addition, there were reported difficulties in obtaining appointments during flares, a lack of dermatologic emergencies, a need to increase human resources and physical space, and a need for telematic consultations for urgent cases. Discrepancies between HCPs’ perceptions and patients’ experiences highlighted unmet needs, particularly in primary care settings and emergency departments. Several strengths were also identified, including satisfactory experience in dermatology, the hospital’s high level of specialisation in the management of complex patients, optimal communication between services, consideration of patient preferences, and proper advice on hospital pharmacy care and administration support of treatment and adherence monitoring. Conclusion: The findings underscore the necessity for interventions to reduce wait times and improve treatment immediacy and effectiveness post-diagnosis. The insights from this study can direct enhancements in patient management and satisfaction for individuals with psoriasis and AD. Plain Language Summary: This study looked into how patients with psoriasis and atopic dermatitis (AD) are treated in a tertiary hospital. It focused on understanding the time it takes for patients to receive help and their satisfaction with the care received. By talking to doctors and patients, the researchers learned about the challenges in the early stages of these diseases and the delays in starting treatment or in the treatment process, among others. They discovered that these patients often wait too long before seeing a dermatologist, leading to a delay in treatment access. The study suggests that quicker diagnosis and treatment could improve how these conditions are managed and increase patient satisfaction.

  • Open Access

    A re‐assessment of the value of markers of corticosteroid contact allergy in the Spanish baseline series: Clobetasol propionate in the spotlight

    by Pedro Mercader‐García, Juan Francisco Silvestre, Francisco Jose Navarro‐Triviño, Ana María Giménez‐Arnau, María Antonia Pastor‐Nieto, Susana Cordoba‐Guijarro, Gemma Melé‐Ninot, Fátima Tous‐Romero, Ricardo González‐Pérez, Inmaculada Ruiz‐González, et al.

    Background: Budesonide and tixocortol pivalate as markers of contact allergy to corticosteroids have been questioned, as they are not able to detect a significant percentage of allergic patients.Objectives: To investigate the potential role of clobetasol propionate in enhancing corticosteroid sensitisation detection.Methods: Between January 2022 and December 2023, patients who attended centres involved in the Spanish Registry of Research in Contact Dermatitis and Cutaneous Allergy were tested with an extended baseline series that included budesonide, tixocortol pivalate, clobetasol propionate 0.1% in ethanol and 1% in petrolatum.Results: A total of 4338 patients were tested. Twenty‐four patients were allergic to budesonide (0.55%, 95% CI: 0.37–0.82); nine patients were allergic to tixocortol pivalate (0.21%, 95% CI: 0.11–0.39); and 23 patients were allergic to clobetasol (0.53%, 95% CI: 0.35–0.79). Only four of those patients allergic to clobetasol were detected by budesonide and one by tixocortol pivalate. No significant differences in the number of positive tests were found between clobetasol in petrolatum or ethanol.Conclusions: In Spain budesonide remains the main corticosteroid allergy marker whereas the role of tixocortol pivalate is questionable. The addition of clobetasol propionate to the Spanish baseline series would improve the ability to detect patients allergic to corticosteroids.


  • Open Access

    EADV Task Force Pruritus White Paper on chronic pruritus and chronic prurigo: Current challenges and future solutions

    by S. Ständer, M. P. Pereira, C. Zeidler, F. J. Legat, L. Misery, L. Lönndahl, A. P. Bewley, E. Brenaut, S. Bobko, J. Elberling, et al.

    Chronic pruritus (CP) is frequent in general medicine and the most common complaint in general dermatology. The prevalence of CP is expected to rise in the future due to the ageing population. The clinical presentation, underlying aetiology and treatment strategy of CP are heterogeneous. Also, individual treatment aims and physical, psychic and economic burdens of patients might vary. Chronic prurigo (CPG) is the most severe disease in the chronic pruritus spectrum, being associated with long‐standing scratch‐induced skin lesions and a therapy refractory itch‐scratch‐cycle. It is thus important to raise disease awareness for CP and CPG in the general public and among decision‐makers in the health system. Further, there is a need to support a rational clinical framework to optimize both diagnostics and therapeutics. Currently, there is still a shortcoming regarding approved therapies and understanding CP/CPG as severe medical conditions. Therefore, the EADV Task Force Pruritus decided to publish this white paper based on several consensus meetings. The group consented on the following goals: (a) ensure that CP is recognized as a serious condition, (b) increase public awareness and understanding of CP and CPG as chronic and burdensome diseases that can greatly affect a person's quality of life, (c) clarify that in most cases CP and CPG are non‐communicable and not caused by a psychiatric disease, (d) improve the support and treatment given to patients with CP to help them manage their disease and (e) publicize existing therapies including current guidelines. We aim to point to necessary improvements in access and quality of care directed to decision‐makers in health policy, among payers and administrations as well as in practical care.


  • Open Access

    Sensitization to textile dyes in Spain: Epidemiological situation (2019–2022)

    by Carlos Pelayo Hernández Fernández, Leopoldo Borrego, Ana María Giménez Arnau, Violeta Zaragoza Ninet, Tatiana Sanz Sánchez, Francisco Javier Miquel Miquel, Ricardo González Pérez, Juan Francisco Silvestre Salvador, Susana Córdoba Guijarro, José Manuel Carrascosa Carrillo, et al.

    Background: Current frequency and features for positivity to textile dye mix (TDM) in Spain are unknown.Objectives: To study the frequency, clinical features and simultaneous positivity between TDM, para‐phenylenediamine (PPD) and specific disperse dyes.Materials and Methods: We analysed all consecutive patients patch‐tested with TDM from the Spanish Contact Dermatitis Registry (REIDAC), from 1 January 2019 to 31 December 2022. Within this group, we studied all selected patients patch‐tested with a textile dye series.Results: Out of 6128 patients analysed, 3.3% were positive to the TDM and in 34% of them, the sensitization was considered currently relevant. TDM positivity was associated with working as a hairdresser/beautician and scalp, neck/trunk and arm/forearm dermatitis. From TDM‐positive patients, 57% were positive to PPD. One hundred and sixty‐four patients were patch‐tested with the textile dye series. Disperse Orange 3 was the most frequent positive dye (16%). One of every six cases positive to any dye from the textile dye series would have been missed if patch‐tested with the TDM alone.Conclusions: Positivity to TDM is common in Spain and often associated with PPD sensitization. TDM is a valuable marker of disperse dyes allergy that should be part of the Spanish and European standard series.


  • Open Access

    Clinical Approach to Patients with Moderate-to-Severe Atopic Dermatitis: A Spanish Delphi Consensus

    by Jose J. Pereyra-Rodriguez, Esther S. Baldrich, Ricardo Ruiz-Villaverde, Eulalia B. Torres, Pablo De la C. Dobao, Ignasi F. Nart, Ángeles F. Menéndez, Ana Martin-Santiago, Javier M. Miquel, Juan F. Silvestre, et al.

    Despite emerging evidence and advances in the management of atopic dermatitis there a lack of consensus regarding the diagnostic criteria, therapeutic approach, method to assess severity, and patient follow-up for this condition. An expert consensus study was conducted to provide recommendations on the management of patients with moderate-to-severe atopic dermatitis. The study used Delphi-like methodology based on a literature review, a summary of the scientific evidence, and a 2-round survey. The agreement of 60 panellists on 21 statements was evaluated. Consensus was pre-defined as ≥ 80% agreement of all respondents. In the first round 6 statements reached consensus. Unanimous consensus was achieved regarding therapeutic goals and patient satisfaction (maintained in the long term and periodic goals reassessment recommended every 3–6 months). In the second round, half of the statements reached consensus, all related to patient follow-up, treatment goals, and atopic comorbidities. The statements that did not reach consensus were related to diagnosis (biomarkers, allergy, and food testing) and starting patients on conventional systemic treatment rather than advanced treatment. The study assessed expert opinion regarding a variety of topics related to the clinical approach to patients with moderate-to-severe atopic dermatitis, in order to provide guidance on the diagnosis and management of patients with atopic dermatitis.


  • Open Access

    Lebrikizumab improved itch and reduced the extent of itch interference on sleep in patients with moderate-to-severe atopic dermatitis: two randomized, placebo-controlled, phase III trials

    by Gil Yosipovitch, Peter A Lio, David Rosmarin, Esther Serra-Baldrich, Franz J Legat, Marta Casillas, Evangeline Pierce, Zhuqing Liu, Luna Sun, Hany Elmaraghy, et al.

    Itch and sleep loss due to itch are prevalent symptoms of moderate-to-severe atopic dermatitis, significantly impairing patients’ quality of life and wellbeing. First-line topical therapy is insufficient for most patients and there is an unmet need for effective treatments that provide symptom relief and quality of life improvement. In two randomized, placebo-controlled, phase III trials, significantly more patients treated with the novel monoclonal antibody lebrikizumab had ≥ 3-point improvement in Pruritus Numeric Rating Scale by week 16 vs. patients treated with placebo. In addition, significantly more patients treated with lebrikizumab achieved ≥ 1-point improvement in Sleep-Loss Scale score by week 16 vs. placebo. Onset of itch relief was rapid, occurring within the first few days of treatment.


  • Open Access

    Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis

    by Helena Iznardo, Esther Roé, Esther Serra-Baldrich, Lluís Puig

    Abrocitinib is a JAK1 selective inhibitor recently approved for the treatment of moderate-to-severe atopic dermatitis in adults. It has demonstrated efficacy and safety in several clinical trials, both in children and adults, in monotherapy, and compared with dupilumab. The expected EASI-75 response rate estimates at week 12 are 62.9% (95% CrI 42.5–79.9%) for abrocitinib 200 mg and 43.0% (95% CrI 24.8–64.0%) for abrocitinib 100 mg. Abrocitinib has shown a faster effect than dupilumab as regards early alleviation of itch. Because of the incomplete target selectivity of JAK inhibitors, when abrocitinib treatment is considered, laboratory screening is necessary, latent tuberculosis must be screened for, active infections are a contraindication, and special caution must be exerted in treating elderly patients and those predisposed to thromboembolic events. Even though recent meta-analyses of clinical trials have not shown that atopic dermatitis, or its treatment with JAK inhibitors or dupilumab, modify the risk of deep venous thrombosis or pulmonary embolism, long-term follow-up studies will better define the safety profile of abrocitinib.


  • Sensitization to isothiazolinones in the Spanish Contact Dermatitis Registry (REIDAC): 2019–2021 epidemiological situation

    by Carlos Pelayo Hernández Fernández, Leopoldo Borrego, Pedro Mercader García, Ana María Giménez Arnau, Javier Sánchez Pérez, Juan Francisco Silvestre Salvador, Ricardo González Pérez, Tatiana Sanz Sánchez, Araceli Sánchez Gilo, Gemma Melé Ninot, et al.

    Background: Current frequency and risk factors for sensitization to methylisothiazolinone (MI), methylchloroisothiazolinone/methylisothiazolinone (MCI/MI), benzisothiazolinone (BIT) and octylisothiazolinone (OIT) in Spain are not well known. Objectives: To study the frequency of sensitization, risk factors and simultaneous sensitization between the four isothiazolinones. Materials and Methods: We analysed all 2019–2021 consecutive patients patch‐tested with MI (0.2% aq.), MCI/MI (0.02% aq.), BIT (0.1% pet.) and OIT (0.1% pet) within the Spanish Contact Dermatitis Registry (REIDAC). Results: A total of 2511 patients were analysed. Frequencies of sensitization were: any isothiazolinone 15.7%, MI 6.8%, MCI/MI 4.8%, BIT 3.5% and OIT 0.5%. MI and MCI/MI sensitization was associated with being occupationally active, hand dermatitis, detergents and age over 40. BIT sensitization was associated with leg dermatitis and age over 40. About one in nine MI‐positive patients were positive to BIT, whereas one in five BIT‐positive patients were positive to MI. Conclusions: Sensitization to MI, MCI/MI and BIT is still common in Spain, while sensitization to OIT is rare. Currently, sensitization to MI and MCI/MI seems to be occupationally related. Although its origin is unknown, sensitization to BIT is more frequent in patients aged over 40 years. Simultaneous sensitization between MI and BIT is uncommon.